About Strados Labs

Improving quality of life for patients with chronic respiratory diseases


Chronic respiratory diseases such as COPD and Asthma affect more than 300 million people and are among the top causes of death worldwide¹. As clinicians and researchers look for new approaches to respiratory disease surveillance and management, Strados Labs developed the RESP Biosensor to allow for improved understanding of patient respiratory health while patients are at home. The RESP Biosensor continuously captures lung sounds including cough, wheeze and crackles in relation to drugs, devices, activity, and more, leading to a stronger understanding of treatment response and earlier insight into exacerbations to prevent unnecessary hospitalizations.

The RESP Biosensor is connected to our proprietary cloud software platform designed to collect and process lung sound data with over 100,000 validated lung sound events and 10 million breaths captured. 

Certifications: FDA 510(k) Cleared Class II, CE Mark, HIPAA Complaint, GDPR Compliant

Clinical Validation: Explore our Studies

Who We Help

Life Sciences

The RESP Biosensor offers drug developers a way to objectively demonstrate treatment effectiveness in reducing respiratory symptoms. From screening to the research phases, our patient-friendly wearable is designed to collect 24-hour cough, wheeze and crackles in daily life, making it an ideal fit for decentralized trials. The RESP Biosensor has been used to measure primary and exploratory endpoints in 4 continents. Learn More

Healthcare Systems: Inpatient

Our technology offers clinical teams an enhanced approach to monitoring at-risk patients in inpatient settings such as hospitals and skilled nursing facilities. By continuously monitoring cough and adventitious lung sounds (wheeze, crackles, rhonchi), care teams can better predict exacerbations and intervene earlier, strengthening outcomes while improving caregiver efficiency. Learn More

Healthcare Systems: Outpatient and Remote Patient Monitoring

Effectively monitoring respiratory patients at home is a challenge for clinicians, with 30-day readmissions for COPD often exceeding 20%². The RESP Biosensor allows care teams to effectively monitor high-risk COPD and Asthma patients, post-acute discharge or after visiting a clinic, offering a better way to assess the care plan and reduce unnecessary hospitalizations. Learn More

*Machine learning algorithms and respiratory rate not FDA-cleared
1. World Health Organization, 2019 Report. Source
2. Predicting and preventing hospital readmission for exacerbation of COPD, 2020. Source 

Our Story

Our team came together at a health hackathon hosted by Independence Blue Cross and Thomas Jefferson University. Strados Labs founder, Nick Delmonico, is a patient who has spent time in the ER and the ICU due to asthma and respiratory illness like RSV. He understands the complexity of properly communicating symptoms and pulmonary status remotely. He wanted to build a better way to get this information into the hands of clinicians to avoid adverse respiratory events.

Since 2016, Strados Labs has successfully transformed the RESP™ Biosensor from an idea to reality with the help of our dedicated team and partners.


Nick Delmonico

Nick Delmonico

CEO & Cofounder

Richard Powers

Richard Powers

Chief Product Officer & Cofounder

Jason Kroh

Jason Kroh

Chief Technology Officer

Shane Krauss

Shane Krauss

Director, Strategy & Business Development

Tom deLaubenfels, PhD

Tom deLaubenfels, PhD

Director, Data Science


Let’s Talk

We’d love to know how we can help you and your patients.